De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy
Nature Genetics2015Vol. 47(4), pp. 393–399
Citations Over TimeTop 1% of 2015 papers
EuroEPINOMICS RES, Steffen Syrbe, Ulrike B. S. Hedrich, Erik Riesch, Tania Djémié, Stephan A. Müller, Rikke S. Møller, Bridget H. Maher, Laura Hernández-Hernández, Matthis Synofzik, Hande Çağlayan, Mutluay Arslan, José M. Serratosa, Michael Nothnagel, Patrick May, Roland Krause, H. Löffler, Katja Detert, Thomas Dorn, Heinrich Vogt, Günter Krämer, Lüdger Schöls, Primus E. Mullis, Tarja Linnankivi, Anna-Elina Lehesjoki, Katalin Štěrbová, Dana Craiu, Dorota Hoffman‐Zacharska, Christian Korff, Yvonne Weber, Maja Steinlin, Sabina Gallati, Astrid Bertsche, Matthias K. Bernhard, Andreas Merkenschlager, Wieland Kieß, Michael Gonzalez, Stephan Züchner, Aarno Palotie, Arvid Suls, Peter De Jonghe, Ingo Helbig, Saskia Biskup, Markus Wolff, Snezana Maljevic, Rebecca Schüle, Sanjay M. Sisodiya, Sarah Weckhuysen, Holger Lerche, Johannes R. Lemke
Related Papers
- → InFUSing antisense oligonucleotides for treating ALS(2022)11 cited
- → The proportion of mutations predicted to have a deleterious effect differs between gain and loss of function genes in neurodegenerative disease(2008)23 cited
- → De Novo and Bi-allelic Pathogenic Variants in NARS1 Cause Neurodevelopmental Delay Due to Toxic Gain-of-Function and Partial Loss-of-Function Effects (4714)(2021)7 cited
- → Maintaining the balance: both gain‐ and loss‐of‐function KCNA2 mutants cause epileptic encephalopathy(2015)3 cited
- → GDF5 is associated with a variety of skeletal malformations due to gain or loss of function mutations(2012)